We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Emv Capital Plc | LSE:EMVC | London | Ordinary Share | GB00BN4R5Q82 | ORD 5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 46.00 | 117 | 08:00:05 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 45.00 | 47.00 | 46.00 | 46.00 | 46.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 2.45M | -3.06M | -0.1118 | -4.79 | 12.58M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 08:12:18 | O | 105 | 47.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 10/6/2025 | 13:28 | UK RNS | EMV Capital PLC TR-1 |
| 06/6/2025 | 15:12 | UK RNS | EMV Capital PLC Notice of AGM and Annual Report & Accounts |
| 04/6/2025 | 14:34 | UK RNS | EMV Capital PLC Director/PDMR Shareholding |
| 04/6/2025 | 12:21 | ALNC |  EMV Capital loss widens on reduced income but assets rise by third |
| 04/6/2025 | 07:00 | UK RNS | EMV Capital PLC Preliminary results for the year ended 31 Dec 2024 |
| 14/5/2025 | 16:02 | UK RNS | EMV Capital PLC PDS: Q1 Results and Clinical and Corporate Update |
| 09/5/2025 | 10:30 | UK RNS | EMV Capital PLC TR-1 |
| 27/3/2025 | 16:46 | UK RNS | EMV Capital PLC PDS: Q4 Results and Clinical Programs Update |
| 07/3/2025 | 16:55 | ALNC | EMV Capital investee initiates phase 3 trial for head and neck cancer |
| 07/3/2025 | 16:26 | UK RNS | EMV Capital PLC PDS: VERSATILE-003 Phase 3 Clinical Trial |
Emv Capital (EMVC) Share Charts1 Year Emv Capital Chart |
|
1 Month Emv Capital Chart |
Intraday Emv Capital Chart |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 22/6/2025 09:20 by Emv Capital Daily Update Emv Capital Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker EMVC. The last closing price for Emv Capital was 46p.Emv Capital currently has 27,357,555 shares in issue. The market capitalisation of Emv Capital is £14,636,292. Emv Capital has a price to earnings ratio (PE ratio) of -4.79. This morning EMVC shares opened at 46p |
Posted at 10/6/2025 04:08 by ohisay Panmure Liberum comment ..EMVC has demonstrated strong operational progress in its core operations, with c. 67% revenue increases, the integration of the Martlet Capital fund now seemingly complete, and the demonstrated ability to generate revenue from multiple avenues, and we continue to see progress towards the strategic operational goal of running core group activities at breakeven. The potential for fair-value creation for very little cash input and disproportionate to in-kind services input has been demonstrated across multiple companies. Successful fundraising in the underlying holdings over 2024 despite challenging headline market conditions points to improving sentiment within the sector. Challenges remain, with market conditions unfavourable to achieving exits, which we think the wider market may be waiting for, but the deep and diversified portfolio offers multiple potential opportunities for significant value creation. The December capital raise has left the balance sheet in a stronger position, and the company has successfully continued to fund operational losses at subsidiary portfolio companies ProAxsis and Glycotest from third party investors, with no balance sheet cash use by the group. Despite this, but somewhat reflecting market conditions at this time, the company remains deeply discounted to its updated SOTP valuation, at c. -69.6%; we retain our Buy Its also the case that the company has materially underperformed the UK VC index over the past 12 months ..I cant post the graph which is quite startling but it underlines that its well overdue a rerate. |
Posted at 04/6/2025 23:28 by sev22 This venture capital fund is in deep value territory.Life science and tech investor only needs one exit to boost sentiment. Published on June 4, 2025 by Simon Thompson * Assets under management up a third to £98.5mn in 2024 * Operating loss widens from £2.6mn to £3.4mn * £2.1mn of cash and liquid holdings at 31 May 2025 * 70 per cent discount to sum-of-the-parts valuation Aim-traded investment and fund management company EMV Capital (EMVC:40p) is performing better than the headline loss suggests. Specialising in the deep tech and life sciences sectors, EMV increased its core revenue two-thirds to £2mn last year. This included £0.7mn of new recurring fund management fees from Martlet Capital, an early-stage investor based in Cambridge that provides patient capital to IP-rich start-ups with high growth potential. In May 2024, EMV was appointed as investment manager to Martlet Capital to manage its portfolio of investments. Reflecting the addition of Martlet’s portfolio, the fair value of EMV’s managed and third-party holdings increased from £38.4mn to £60.8mn in the 12-month reporting period, rising to £64.7mn on 31 May 2025. Although the fair valuation of EMV’s direct holdings dipped 6 per cent to £37.7mn (135p), largely due to a fall in the value of Nasdaq-listed PDS Biotechnology Corporation (US:PDSB), it has since recovered to £38.3mn (137p). It means total assets under management (AUM) have risen from £98.5mn to £103mn since the financial year-end, up from £74mn at the end of 2023. Core revenue covers 58 per cent of core costs of £3.5mn, so the operating loss attributed to EMV’s core operations was £1.5mn. Subsidiary portfolio companies ProAxsis and Glycotest contributed a loss of £2.2mn, but are being funded by external investors and are not a cash burden on group operations. EMV retained cash and listed holdings of £2.1mn on 31 May 2025, so has no immediate cash funding requirements. A portfolio with substantial value. Across EMV’s direct portfolio, 13 companies raised £105mn in equity and debt funding last year, which earned EMV £0.7mn of corporate finance fees from syndicating £8.6mn in new investments. In addition, Martlet portfolio companies raised £171mn in new funding. EMV now has direct and indirect interests across more than 70 companies in the deep tech and life sciences sectors that are at differing stages in their growth cycles. Notable names include NuQuantum (quantum computing), Paragraf (graphene-based semi-conductors), Cambridge GaN Devices (power electronics), Oxford Space Systems (satellite communications). Also, EMV holds valuable carried interests from its growing third party assets under management. These typically range from 15 to 20 per cent of accumulated profits earned for investors above a minimum return hurdle rate of 10 per cent. On a sum-of-the-parts (SOTP) basis, analysts at Panmure Liberum’s fair valuation of £37mn (133p) is more than three times EMV’s market capitalisation of £11.1mn (40p), highlighting the deep value on offer. True, portfolio exits will be needed to provide investors with confidence that valuations can be realised and achieving exits remains challenging in the current unfavourable market conditions. However, it would only take one significant exit to improve investor sentiment markedly and narrow the 70 per cent share price discount to SOTP valuations. So, having recommended buying the shares, at 64p, in my 2023 Bargain Share Portfolio and suggested participating in the retail offer when EMV raised £1.5mn, at 50p (‘A share offer that’s hard to refuse’, 3 December 2024), I would continue to hold your shares. HOLD. |
Posted at 04/6/2025 08:49 by loafofbread 2024 saw EMV Capital plc continue to make good use of its AIM quotation demonstrated through the £1.5 million Placing in December 2024, alongside the issuance of shares to Q-Bot and to several suppliers in lieu of cash. We continue to see the benefit of our AIM quotation, particularly in our ability to selectively issue shares to strategic counterparties and as a differentiator to other VC peers, providing an added layer of 'institution grade' confidence to co-investors and portfolio companies.Staying on Aim, NAV £37.7M vs £11M M CAP. Good and bad news in the results but nothing to warrant a 40p share price. Lots of their companies doing very well so looking forward to the updates. |
Posted at 02/6/2025 16:28 by senttothegallows 9% increase in pdsb share price increase EMV discount to NAV even more. Results for EMV will be very interesting in my opinion |
Posted at 15/4/2025 11:09 by 888icb A 9% rise on volume of 75000 from 9 trades shows it doesn’t take much volume to move this share. This share continues to trade at a very large discount to its NAV as was pointed out by Simon Thompson in his most recent article in December 2024 when he recommended taking up the 50p offer for new shares. The article concluded:“ Assuming full subscription of both the retail offer and subscription, EMV will have 27.36mn shares in issue, implying the directly held portfolio is worth around 152p per share, or more than three times the current share price. So, having outlined a strong investment case when I last suggested buying the shares, at 51.5p (‘A venture capital company on a huge discount’, 1 October 2024), I would recommend participating in the retail offer. Buy.” Let’s hope we don’t have to wait too much longer for Simon’s recommendation to come good. |
Posted at 30/1/2025 12:38 by 888icb There was the Qbot fundraising on 31/12/24 and the Wanda Health Fundraising on 9/12/24 so it’s 1 month without news. But I agree the share price performance is currently disappointing,partic“ Assuming full subscription of both the retail offer and subscription, EMV will have 27.36mn shares in issue, implying the directly held portfolio is worth around 152p per share, or more than three times the current share price. So, having outlined a strong investment case when I last suggested buying the shares, at 51.5p (‘A venture capital company on a huge discount’, 1 October 2024), I would recommend participating in the retail offer. Buy.” |
Posted at 06/1/2025 13:33 by kingston78 Panmure Liberum has reduced its share price target from 157p to 149p, which still provides plenty of upside for the share price.This is the bargain of the year. Sooner or later one or more of the company's investments will be cashed in for significant gain. |
Posted at 03/12/2024 13:25 by sev22 A share offer that's hard to refuse.Venture capital and fund firm’s offer to retail shareholders is well worth participating in. Published on December 3, 2024 by Simon Thompson *£1.5mn subscription and retail offer *Wanda Health investment generates 2,077 per cent capital return in only six months *£41mn directly held portfolio *£65.7mn managed and third-party funds under management *68 per cent share price discount to proforma value of portfolio post equity raise Aim-traded investment and fund management company EMV Capital (EMVC:49p), formerly Netscientific, is raising £1.5mn through a subscription and retail offer of new shares at 50p. Specialising in the deep tech and life sciences sectors, EMV aims to deliver shareholder value by identifying and investing in companies with transformative technologies both within the UK and internationally. The strategy focuses on achieving capital returns through the profitable exits of selected portfolio companies, as well as generating carried interest from a growing funds practice, which surpassed £100mn of assets under management in the first half of 2024. The growth in the fair value of EMV’s directly held holdings has been notable since I included the shares in my 2023 Bargain Share Portfolio. In particular, a cohort of four portfolio companies in which EMV invested £0.4mn of cash and £0.4mn of in-kind services are now worth £7.1mn. They account for almost a fifth of the £38.5mn valuation of EMV’s directly held unquoted investment portfolio. The hefty revaluations reflect the read through valuations when unlisted portfolio companies raise new capital. For instance, EMV’s 21.1 per cent stake in one of the four investee companies, plastic recycling technology business DeepTech Recycling, has been valued at £1.8mn following a syndicated fundraising round led by EMV. DeepTech offers an innovative solution to the environmental challenges of plastic pollution. Other investee companies set for large revaluations. In addition, EMV’s management revealed in the fundraising document that portfolio company, Wanda Health, is expected to complete a £1mn equity funding round on 6 December 2024 at a pre-money valuation of £5mn. In May 2024, EMV acquired a 30 per cent stake in the company for £62,000, which was paid for by in-kind services. Wanda Health has commercialised an intelligent platform for remote patient monitoring and virtual care. It collects data from patients' homes or community settings, and provides it to clinicians, highlighting high risks cohorts. Effectively, the platform provides healthcare providers with data to detect exacerbations early in patients with acute, chronic, and specialty diseases, helping them speed up interventions, prevent adverse events, and improve patient adherence. EMV’s fully diluted 22.5 per cent stake in Wanda Health will have a read through valuation of £1.35mn post this week’s funding round, representing almost a 22 times increase on its investment in only six months. Sensible use of EMV’s fundraise. The proceeds of EMV’s equity raise will be used for working capital, to develop the infrastructure of the company’s wholly owned corporate finance and venture capital firm in response to growth in the syndicated investor base, and to provide ‘dry powder’ for capital investments. That’s sensible given the valuation creation the approach is now delivering. EMV’s subscription offer is raising £0.88mn at 50p per share through a bookbuild process and the WRAP retail offer aims to raise £0.62mn from existing retail shareholders at the same price through participating financial intermediaries. The retail offer closes at 4.30pm on 4 December 2024, so you have a short timeframe to participate. It’s worth doing so given the undervaluation of EMV. To put this into perspective, the last reported £41mn director valuation of the directly held (quoted and unquoted) portfolio is more than three times the company’s market capitalisation of £12mn (49p). The portfolio valuation excludes the post period end £1.3mn uplift on the Wanda Health equity stake, half of which will be offset by the second half decline in the market value (from £2.5mn to £1.8mn) of EMV’s shareholding in Nasdaq-listed PDS Biotechnology Corporation (US:PDSB), a clinical-stage company that is developing cancer immunotherapies and infectious disease vaccines. Assuming full subscription of both the retail offer and subscription, EMV will have 27.36mn shares in issue, implying the directly held portfolio is worth around 152p per share, or more than three times the current share price. So, having outlined a strong investment case when I last suggested buying the shares, at 51.5p (‘A venture capital company on a huge discount’, 1 October 2024), I would recommend participating in the retail offer. BUY. |
Posted at 16/10/2024 09:25 by 1gw Just trying to get a conversation going loaf. I looked at the interims for the values in my previous post, but there's more detail in the full-year results (prelims):£371k End-2021 £415k End-2022 £333k End-2023 based on Series C raise So we might presume that there will be a fresh valuation at end-year based on the implied equity value in the Series D raise just announced. This was from the 2023 prelims: "CytoVale Inc., (1.0% stake) remains privately held, and fair value has been established using the share price and company valuation from investments by third parties during November 2023 as part of an $84m Series C equity round that raised fresh cash of $53m and conversion of outstanding convertible notes. Fair value at year end was £333k (2022: £415k). This last observable price has been used to value the CytoVale equity investment at year end." And this from 2022 prelims: "CytoVale Inc., (1.0% stake) remains privately held, and fair value has been established using the share price and company valuation from investments by third parties during December 2019. CytoVale raised $15.0m all at the same price per share from VC, private investor and government sources. At the time this was the only observable valuation on which to value CytoVale. Fair value at year end was £415k (2021: £371k). This last observable price has been used to value the CytoVale equity investment at year end." |
Posted at 15/10/2024 20:32 by 1gw The sepsis test sounds very interesting. It's very difficult though to work out what new funding rounds mean for EMVC's interest because we don't know what rights come with the various funding rounds - do we?EMVC's stake was valued at £0.4m in the 2022 interims and the 2023 interims, vs the £0.3m in the latest interims. So it appears the value has gone down, at least before the Series D round. If you look at funding rounds, it appears they went as follows: $4.3m Series A 2014 (EMVC participated) $7.25m Series B 2017 $84m Series C November 2023 $100m Series D October 2024 So if EMVC's 1% equity, which was quoted in the 2022 interims (i.e. as of 30th June 2022), has remained unchanged up to the latest interims as of 30th June 2024 (i.e. after Series C), while the value appears to have gone down after the Series C raise then what have investors got who participated in the much bigger Series C and now Series D rounds? Have they got some sort of preferred equity, or warrants, or anti-dilution rights in future raises which EMVC doesn't have? i.e. is EMVC's "1%" likely to be materially diluted through rights held by Series C and D investors (maybe even Series B) if it ever gets to IPO or sale? |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
